Agios Pharmaceuticals, Inc. (AGIO)Healthcare | Biotechnology | Cambridge, United States | NasdaqGS
26.77 USD
-0.31
(-1.127%) ⇩
(April 21, 2026, 10:29 a.m.
EDT)
Short-term: ★★★★☆ | Long-term: ★★★☆☆ | Dividends: ★☆☆☆☆ |
Hot Take | April 19, 2026, 12:08 a.m. EDT
AGIO presents a compelling high-conviction momentum trade driven by recent strong price action and institutional buying, supported by a bullish options flow that targets upside above the current price, though structural stagnation in 86% revenue growth and multi-year losses necessitates a long-term hold rather than blind investment. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.063268 |
| AutoARIMA | 0.064982 |
| AutoETS | 0.064999 |
| MSTL | 0.066874 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 37% |
| H-stat | 11.00 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.033 |
| Excess Kurtosis | -0.70 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 3.37 |
| Revenue per Share | 0.932 |
| Market Cap | 1,568,219,392 |
| Forward P/E | -5.47 |
| Beta | 0.79 |
| Website | https://www.agios.com |
As of April 19, 2026, 12:08 a.m. EDT: Options activity displays a distinct short-term bullish skew with significant Call Open Interest (OI) clustering at strikes 35.0 (ATM/POTM) and 40.0 for the May 15, 2026 expiration. The Call distribution shows +13.8% positioning at the 40.0 strike, suggesting a hedge rate or target above current prices. Conversely, Put OI is heavily concentrated at downside strikes (e.g., 30.0), functioning more as profit protection given the strong near-term rally (16.3% gain in the last two weeks) rather than a distribution of bearish bets. Longer-term Call chains (Dec '26, Jan '27) show increasing OI at strikes 45.0 and 50.0, indicating some positioning for continued recovery, though volume remains lower than the front month.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.03321427 |
| Address1 | 88 Sidney Street |
| All Time High | 138.85 |
| All Time Low | 15.77 |
| Ask | 34.29 |
| Ask Size | 2 |
| Audit Risk | 3 |
| Average Analyst Rating | 1.6 - Buy |
| Average Daily Volume10 Day | 1,359,850 |
| Average Daily Volume3 Month | 995,108 |
| Average Volume | 995,108 |
| Average Volume10Days | 1,359,850 |
| Beta | 0.785 |
| Bid | 19.24 |
| Bid Size | 2 |
| Board Risk | 2 |
| Book Value | 20.413 |
| City | Cambridge |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 4 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 26.765 |
| Current Ratio | 11.46 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 27.01 |
| Day Low | 26.43 |
| Debt To Equity | 3.37 |
| Display Name | Agios Pharmaceuticals |
| Earnings Call Timestamp End | 1,777,464,000 |
| Earnings Call Timestamp Start | 1,777,464,000 |
| Earnings Timestamp | 1,777,465,800 |
| Earnings Timestamp End | 1,777,465,800 |
| Earnings Timestamp Start | 1,777,465,800 |
| Ebitda | -466,955,008 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.653 |
| Enterprise To Revenue | 14.287 |
| Enterprise Value | 771,872,128 |
| Eps Current Year | -6.51 |
| Eps Forward | -4.89125 |
| Eps Trailing Twelve Months | -7.12 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 29.942 |
| Fifty Day Average Change | -3.177 |
| Fifty Day Average Change Percent | -0.10610514 |
| Fifty Two Week Change Percent | -3.321427 |
| Fifty Two Week High | 46.0 |
| Fifty Two Week High Change | -19.235 |
| Fifty Two Week High Change Percent | -0.41815218 |
| Fifty Two Week Low | 22.24 |
| Fifty Two Week Low Change | 4.5249996 |
| Fifty Two Week Low Change Percent | 0.20346221 |
| Fifty Two Week Range | 22.24 - 46.0 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,374,672,600,000 |
| Float Shares | 49,738,895 |
| Forward Eps | -4.89125 |
| Forward P E | -5.472016 |
| Free Cashflow | -267,967,504 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 539 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Gross Profits | -291,852,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01123 |
| Held Percent Institutions | 1.06329 |
| Implied Shares Outstanding | 58,592,172 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. |
| Long Name | Agios Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 1,568,219,392 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_46539787 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -412,780,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,585,504,174 |
| Number Of Analyst Opinions | 8 |
| Open | 26.84 |
| Operating Cashflow | -372,976,992 |
| Operating Margins | -6.08895 |
| Overall Risk | 4 |
| Payout Ratio | 0.0 |
| Phone | 617 649 8600 |
| Previous Close | 27.07 |
| Price Eps Current Year | -4.1113667 |
| Price Hint | 2 |
| Price To Book | 1.3111743 |
| Price To Sales Trailing12 Months | 29.026049 |
| Profit Margins | 0.0 |
| Quick Ratio | 10.525 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.6 |
| Region | US |
| Regular Market Change | -0.3050003 |
| Regular Market Change Percent | -1.1267097 |
| Regular Market Day High | 27.01 |
| Regular Market Day Low | 26.43 |
| Regular Market Day Range | 26.43 - 27.01 |
| Regular Market Open | 26.84 |
| Regular Market Previous Close | 27.07 |
| Regular Market Price | 26.765 |
| Regular Market Time | 1,776,781,787 |
| Regular Market Volume | 179,182 |
| Return On Assets | -0.19935 |
| Return On Equity | -0.30195 |
| Revenue Growth | 0.861 |
| Revenue Per Share | 0.932 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 7 |
| Shares Outstanding | 58,592,172 |
| Shares Percent Shares Out | 0.11270001 |
| Shares Short | 6,606,016 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 6,239,478 |
| Short Name | Agios Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.11359999 |
| Short Ratio | 7.2 |
| Source Interval | 15 |
| State | MA |
| Symbol | AGIO |
| Target High Price | 65.0 |
| Target Low Price | 28.0 |
| Target Mean Price | 43.75 |
| Target Median Price | 41.5 |
| Total Cash | 854,425,024 |
| Total Cash Per Share | 14.583 |
| Total Debt | 40,207,000 |
| Total Revenue | 54,028,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -7.12 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 33.7462 |
| Two Hundred Day Average Change | -6.981201 |
| Two Hundred Day Average Change Percent | -0.2068737 |
| Type Disp | Equity |
| Volume | 179,182 |
| Website | https://www.agios.com |
| Zip | 2,139 |